H. Lukka

发表

Long-term results of hypofractionated radiation therapy for breast cancer.

Anthony Fyles, Jean-Philippe Pignol, Laval Grimard, 2010, The New England journal of medicine.

Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways

R. Bristow, Gurmit Singh, T. Tsakiridis, 2011, Radiation oncology.

A randomized trial comparing a combination of iridium implant and external beam radiation to external beam radiation alone for patients with locally advanced prostate cancer

M. Levine, J. Julian, H. Lukka, 2004 .

Use of adjuvant chemotherapy following cystectomy in patients with deep muscle-invasive transitional cell carcinoma of the bladder

J. Chin, M. Brundage, R. Segal, 2003 .

Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix

T. Whelan, Glenn W. Jones, James R. Wright, 1994 .

Accuracy of ultrasound in localization of breast boost field.

T. Whelan, J. Ringash, H. Reiter, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.

C. Catton, É. Vigneault, J. Crook, 2015, International journal of radiation oncology, biology, physics.

External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

C. Catton, D. Taussky, J. Crook, 2017, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Maximal androgen blockade for the treatment of metastatic prostate cancer—a systematic review

J. Trachtenberg, L. Klotz, E. Winquist, 2006, Current oncology.

Salvage radiotherapy following biochemical relapse after radical prostatectomy: proceedings of the Genito-Urinary Radiation Oncologists of Canada consensus meeting.

P. Warde, T. Pickles, G. Morton, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Development of ProCaRS Clinical Nomograms for Biochemical Failure-free Survival Following Either Low-Dose Rate Brachytherapy or Conventionally Fractionated External Beam Radiation Therapy for Localized Prostate Cancer

C. Catton, J. Crook, G. Rodrigues, 2015, Cureus.

Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

F. Saad, L. Klotz, T. Pickles, 2020, The Journal of urology.

Baseline staging of newly diagnosed prostate cancer: a summary of the literature.

H. Lukka, I. Dayes, S. Abuzallouf, 2004, The Journal of urology.

Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Ronald B. Moore, F. Saad, L. Eapen, 2020, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Single-center experience with radium-223 in patients with castration-resistant prostate cancer and bone metastases

A. Kapoor, S. Hotte, Yuding Wang*, 2019, Asian journal of andrology.

Prostate cancer: risk categories and role of hormones and radiotherapy.

H. Lukka, 2002, The Canadian journal of urology.

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

D. Conen, J. Chin, L. Klotz, 2020, The Journal of urology.

Surveillance programs for early stage non-seminomatous testicular cancer: a practice guideline.

M. Johnston, L. Klotz, H. Lukka, 2001, The Canadian journal of urology.

Prostate cancer radiotherapy 2002: the way forward.

C. Catton, P. Warde, T. Pickles, 2005, The Canadian journal of urology.

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

T. Whelan, E. Eisenhauer, H. Kitchener, 2009, The Lancet.

The use of bisphosphonates in men with hormone-refractory prostate cancer: a systematic review of randomized trials.

S. Berry, E. Winquist, H. Lukka, 2006, The Canadian journal of urology.

14 Randomized Trial Comparing Iridium Plus External-Beam Radiation Therapy with External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate

H. Lukka, J. Sathya, M. Levin, 2005 .

GU radiation oncologists consensus on bone loss from androgen deprivation.

G. Duncan, P. Warde, T. Pickles, 2006, The Canadian journal of urology.

Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis.

F. Saad, A. Kapoor, H. Lukka, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

A. Kiss, P. Cheung, C. Danjoux, 2013, International journal of radiation oncology, biology, physics.

In favour of bladder preservation using combined modality treatment.

H. Lukka, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA.

D. Grignon, A. Zietman, H. Sandler, 2016 .

Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial

D. Low, H. Sandler, É. Vigneault, 2018, International Journal of Radiation Oncology*Biology*Physics.

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer.

J. Crook, K. Gulenchyn, A. McEwan, 1993, International journal of radiation oncology, biology, physics.

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

C. Catton, P. Warde, G. Bauman, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.

W. J. Morris, P. Warde, M. Brundage, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.

L Souhami, M. Brundage, D. Tu, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Management of stage I seminomatous testicular cancer: a systematic review.

P. Warde, P. Chung, E. Winquist, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

S. Hotte, S. Berry, E. Winquist, 2006, BMC Cancer.

Pre-treatment risk stratification of prostate cancer patients: A critical review.

P. Warde, M. Brundage, J. Crook, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.

M. Johnston, J. Crook, L. Klotz, 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Protocol for a phase III RCT and economic analysis of two exercise delivery methods in men with PC on ADT

G. Tomlinson, P. Warde, G. Tomlinson, 2018, BMC Cancer.

The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review.

C. Catton, P. Warde, M. Brundage, 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer.

Anthony Fyles, Laval Grimard, Mark Levine, 2002, Journal of the National Cancer Institute.

Timing of Androgen Deprivation Therapy for Prostate Cancer Patients after Radiation: Planned Combined Analysis of Two Randomized Phase 3 Trials

Ryan L. Smith, M. Stockler, G. Pond, 2018, International Journal of Radiation Oncology*Biology*Physics.

Timing of androgen deprivation therapy for prostate cancer patients after radiation: Planned combined analysis of two randomized phase 3 trials.

M. Stockler, G. Pond, H. Woo, 2018 .

Adjuvant radiotherapy following radical prostatectomy: Genito-Urinary Radiation Oncologists of Canada Consensus Statement.

P. Warde, T. Pickles, G. Morton, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Randomized Trial of Breast Irradiation Schedules After Lumpectomy for Women With Lymph Node-Negative Breast Cancer

T. Whelan, A. Fyles, M. Levine, 2002 .

The relationship between the bladder and the cervix in patients undergoing intracavitary therapy.

C. Moore, R. Hunter, H. Lukka, 1987, The British journal of radiology.

Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.

M. Brundage, J. Crook, H. Lukka, 1998, Cancer prevention & control : CPC = Prevention & controle en cancerologie : PCC.

Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis.

J. Chin, E. Winquist, H. Lukka, 2004, The Journal of urology.

Review Article NEOADJUVANT CHEMOTHERAPY FOR TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A SYSTEMATIC REVIEW AND META-ANALYSIS

J. Chin, E. Winquist, H. Lukka, 2004 .

Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01.

Christopher U. Jones, R. Mak, H. Sandler, 2016, Urologic oncology.

Acute Toxicity and Quality of Life of Hypofractionated Radiotherapy for Breast Cancer.

T. Whelan, J. Arsenault, E. Rakovitch, 2015, International journal of radiation oncology, biology, physics.

High dose rate versus low dose rate brachytherapy for squamous cell carcinoma of the cervix: an economic analysis.

H. Lukka, G. Jones, B. O'Brien, 1994, The British journal of radiology.

Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.

Qing Guo, Mark Levine, M. Levine, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer

W. Sharieff, H. Lukka, I. Dayes, 2016, Technology in cancer research & treatment.

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis.

L. Eapen, E. Winquist, H. Lukka, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Breast irradiation postlumpectomy: development and evaluation of a decision instrument.

D. Streiner, A. Gafni, T. Whelan, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prostate cancer risk stratification (ProCaRS) project: recursive partitioning risk stratification analysis.

C. Catton, P. Warde, M. Brundage, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Re: Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer.

F. Saad, L. Klotz, T. Pickles, 2020, The Journal of urology.

Patient Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase II Study Evaluating 2 Ultrahypofractionated Regimens (UHR) for Prostate Cancer (CaP)

I. Kaplan, D. Beyer, H. Sandler, 2020, International Journal of Radiation Oncology*Biology*Physics.

Controversies in prostate cancer radiotherapy: consensus development.

L Souhami, G Morton, M. Brundage, 2001, The Canadian journal of urology.

High-intensity focused ultrasound for prostate cancer: a systematic review.

G Rodrigues, J. Chin, P. Warde, 2011, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adherence to oral hormonal therapy in advanced prostate cancer: a scoping review

S. Alibhai, K. Connelly, N. Fleshner, 2023, Therapeutic advances in medical oncology.

The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments.

T. Tsakiridis, H. Lukka, I. Dayes, 2021, Clinical genitourinary cancer.

High-intensity focused ultrasound for prostate cancer: a practice guideline.

J. Chin, P. Warde, G. Rodrigues, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Phase II study to evaluate the toxicity and efficacy of concurrent cisplatin and radiation therapy in the treatment of patients with locally advanced squamous cell carcinoma of the cervix.

M. Brundage, R. Pearcey, G. Stuart, 1995, Gynecologic oncology.

Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.

J. Chin, M. Brundage, E. Winquist, 2002, The Canadian journal of urology.

Adjuvant External Beam Radiotherapy in the Treatment of Endometrial Cancer: Results of the Randomized MRC ASTEC and NCIC CTG EN.5 Trials, A Systematic Review and Meta-analysis

M. Parmar, T. Whelan, W. Qian, 2008 .

Inhibition of carbonic anhydrase IX (CA9) sensitizes renal cell carcinoma to ionizing radiation.

Diana L. Glennie, T. Farrell, J. Pinthus, 2015, Oncology reports.

Patient preference for high or low dose rate brachytherapy in carcinoma of the cervix.

T. Whelan, H. Lukka, G. Jones, 1995, Radiotherapy and Oncology.

High-intensity Focused Ultrasound for Prostate Cancer

J. Chin, P. Warde, G. Rodrigues, 2012 .

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations

L. Eapen, E. Winquist, H. Lukka, 2008 .

Patient-Reported Outcomes in NRG Oncology/RTOG 0938, a Randomized Phase 2 Study Evaluating 2 Ultrahypofractionated Regimens (UHRs) for Prostate Cancer

I. Kaplan, D. Beyer, H. Sandler, 2016 .

The prostate cancer risk stratification project: database construction and risk stratification outcome analysis.

C. Catton, P. Warde, M. Brundage, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).

A. Wyatt, K. Ding, M. Brundage, 2022, Journal of Clinical Oncology.

Hormone use after radiotherapy failure: a survey of Canadian uro-oncology specialists.

L. Klotz, T. Pickles, P. Cheung, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Report of NRG Oncology/RTOG 9601, A Phase 3 Trial in Prostate Cancer: Anti-androgen Therapy (AAT) With Bicalutamide During and After Radiation Therapy (RT) in Patients Following Radical Prostatectomy (RP) With pT2-3pN0 Disease and an Elevated PSA

D. Grignon, A. Zietman, H. Sandler, 2016 .

A. Kiss, P. Cheung, C. Danjoux, 2013, International journal of radiation oncology, biology, physics.

Adjuvant radiotherapy in women with stage I endometrial cancer: a systematic review.

J. Kwon, A. Fyles, L. Elit, 2006, Gynecologic oncology.

Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.

C. Catton, É. Vigneault, J. Crook, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: guideline recommendations

L. Eapen, E. Winquist, H. Lukka, 2008 .

The Technique, Resources and Costs of Stereotactic Body Radiotherapy of Prostate Cancer

W. Sharieff, H. Lukka, I. Dayes, 2016, Technology in Cancer Research and Treatment.

Primitive neuroectodermal tumors of the uterus: a report of four cases.

P. Clement, H. Lukka, D. Daya, 1992, Human pathology.